Delivery Order SPE2DR25D9311-SPE2DR26FSBD8
- Not listed
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $20,592.96 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 1,000 unit vials of Kcentra. The award was issued on November 24, 2025, with an ultimate completion date of December 16, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order falls...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,901.76 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 1,000 units of Kcentra. The award, issued on October 29, 2025, utilizes firm fixed-price pricing with no set-aside designation, indicating DMS Pharmaceutical Group competed successfully in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's...
- The Defense Logistics Agency awarded a delivery order valued at $13,546.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 500-unit vials of Kcentra. The delivery order, issued on June 18, 2025, with an ultimate completion date of July 11, 2025, employs firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $21,888.00 to DMS Pharmaceutical Group Inc. for the supply of Kcentra 500 unit vials. This delivery order, issued on August 6, 2025, with an ultimate completion date of August 27, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which carries a total value of $499,999,999 and extends through November 2026. The delivery will be...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for 1,000 unit vials of Kcentra, valued at approximately $69.7K. This firm fixed-price delivery order, with an ultimate completion date of October 8, 2025, was issued without a set-aside designation. The award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $18,641.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 1,000 unit vials of Kcentra. This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of August 18, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 25, 2025, by the Defense Logistics Agency (DLA) for 1,000 unit vials of Kcentra, a vitamin K-dependent clotting factor concentrate used to reverse anticoagulation. The firm fixed-price delivery order has a ceiling value of $19,845.12 with an ultimate completion date of August 15, 2025. This award was issued without a set-aside designation,...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $3,307.52 for 1,000 units of Kcentra under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award was issued on September 15, 2025, with an ultimate completion date of October 10, 2025. This delivery order carries no set-aside designation and represents performance at the contractor's Park...
- The Defense Logistics Agency awarded a delivery order valued at $9,857.28 to DMS Pharmaceutical Group Inc. for 1,000 unit vials of Kcentra on September 27, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price delivery order represents no set-aside designation and will be performed in Park Ridge, Illinois, where DMS Pharmaceutical Group maintains its headquarters. Kcentra is a vitamin K-dependent clotting factor complex used to reverse anticoagulation in emergency...
- The Defense Logistics Agency awarded a delivery order valued at $39,520 to DMS Pharmaceutical Group Inc. for 1,000 unit vials of Kcentra, a vitamin K-dependent clotting factor complex used for rapid reversal of warfarin anticoagulation. This firm fixed-price delivery order, issued on August 12, 2025, with ultimate completion by September 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November...
- SPE2DR25D9311Indefinite Delivery Contract
- SPE2DR25D9311-SPE2DR26FSBD8Delivery Order
The Defense Logistics Agency awarded a $3,106.88 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 1,000 unit vials of Kcentra. The delivery order, issued December 1, 2025, with an ultimate completion date of December 22, 2025, carries no set-aside designation, indicating the vendor competed in unrestricted federal procurement. This award falls under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, designated as contract SPE2DR, which was established November 13, 2025, with a $499.999 billion ceiling value through December 31, 2036. Kcentra, a prothrombin complex concentrate used for urgent reversal of warfarin anticoagulation, represents a critical specialty pharmaceutical product within DLA's broader effort to maintain comprehensive medical supply chains supporting Department of Defense healthcare facilities worldwide. As a regional prime vendor under the $30.3 billion PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group has demonstrated substantial contracting capability across diverse therapeutic categories and product lines. The vendor maintains no identified subcontractor relationships, directly fulfilling pharmaceutical supply requirements across multiple therapeutic areas including oncology treatments, biologics, vaccines, and emergency medications to support military medical operations globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 11/30/25 |